{"DataElement":{"publicId":"5979456","version":"1","preferredName":"Invasive Breast Carcinoma Mitotic Rate Nottingham Histologic Score Outcome","preferredDefinition":"Results of the Nottingham histologic score for mitoses identified by microscopic examination of a breast specimen.","longName":"IBC_MIRT_NOTSC_OUTCM","context":"NCI Standards","contextVersion":"1","DataElementConcept":{"publicId":"5979452","version":"1","preferredName":"Invasive Breast Carcinoma Mitotic Count","preferredDefinition":"A carcinoma that infiltrates the breast parenchyma.  The vast majority are adenocarcinomas arising from the terminal ductal lobular unit (TDLU).  Often, the invasive adenocarcinoma co-exists with ductal or lobular carcinoma in situ.  It is the most common carcinoma affecting women._The number of mitoses identified under the microscope in tumors.  It is one of the parameters that determine the grade of malignant tumors.  The method of counting varies, according to the specific tumor examined.  Usually the mitotic count is determined based on the number of mitoses per high power field (40X) or 10 high power fields.","longName":"2431278v1.0:2431222v1.0","context":"NCI Standards","contextVersion":"1","ObjectClass":{"publicId":"2431278","version":"1","preferredName":"Invasive Breast Carcinoma","preferredDefinition":"A carcinoma that infiltrates the breast parenchyma.  The vast majority are adenocarcinomas arising from the terminal ductal lobular unit (TDLU).  Often, the invasive adenocarcinoma co-exists with ductal or lobular carcinoma in situ.  It is the most common carcinoma affecting women. --2003","longName":"C9245","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Invasive Breast Carcinoma","conceptCode":"C9245","definition":"A carcinoma that infiltrates the breast parenchyma.  The vast majority are adenocarcinomas arising from the terminal ductal lobular unit (TDLU).  Often, the invasive adenocarcinoma co-exists with ductal or lobular carcinoma in situ.  It is the most common carcinoma affecting women.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"05DCF1A1-FAC7-3A7D-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-11-18","endDate":null,"createdBy":"UMLLOADER_CAP","dateCreated":"2005-11-18","modifiedBy":"SBREXT","dateModified":"2007-11-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2431222","version":"1","preferredName":"Mitotic Count","preferredDefinition":"definition pending","longName":"C47864","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Mitotic Count","conceptCode":"C47864","definition":"The number of mitoses identified under the microscope in tumors.  It is one of the parameters that determine the grade of malignant tumors.  The method of counting varies, according to the specific tumor examined.  Usually the mitotic count is determined based on the number of mitoses per high power field (40X) or 10 high power fields.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"05DCE31E-478E-3314-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-11-18","endDate":null,"createdBy":"UMLLOADER_CAP","dateCreated":"2005-11-18","modifiedBy":"SBREXT","dateModified":"2007-11-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008557","version":"1","preferredName":"Lab Results","preferredDefinition":"the results of laboratory tests.","longName":"LAB_RESULTS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B2CFBA7D-D009-7227-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-27","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-27","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NCI CRF Standards","workflowStatus":"RELEASED","registrationStatus":"Standard","id":"592A743E-A669-487D-E053-F662850A9518","latestVersionIndicator":"Yes","beginDate":"2017-09-14","endDate":null,"createdBy":"TAYLORT","dateCreated":"2017-09-14","modifiedBy":"HARTLEYG","dateModified":"2018-06-06","changeDescription":"9/19/17 tt released.  9/14/17 tt New DEC, added CSI per Round 5 finalization task; replaces DEC 2431349.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"5979447","version":"1","preferredName":"Nottingham Histologic Score Mitotic Rate Outcome","preferredDefinition":"A numeric representation combining three histologic reporting elements, tubule formation, nuclear pleomorphism and mitotic count, to determine the grade of breast cancer.  The Nottingham Score is a factor in determining the Nottingham Prognostic Index._The number of mitoses identified under the microscope in tumors.  It is one of the parameters that determine the grade of malignant tumors.  The method of counting varies, according to the specific tumor examined.  Usually the mitotic count is determined based on the number of mitoses per high power field (40X) or 10 high power fields._The result of an action.","longName":"5979447v1.0","context":"NCI Standards","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":"7","maxLength":"50","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Score 3","valueDescription":"Mitotic Rate Score 3","ValueMeaning":{"publicId":"5979448","version":"1","preferredName":"Mitotic Rate Score 3","longName":"5979448","preferredDefinition":"A finding of greater than or equal to 8 mitoses per mm2 (greater than 15 per 10 hpf).","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Mitotic Rate Score 3","conceptCode":"C138985","definition":"A finding of greater than or equal to 8 mitoses per mm2 (greater than 15 per 10 hpf).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"592A743E-A5C9-487D-E053-F662850A9518","latestVersionIndicator":"Yes","beginDate":"2017-09-14","endDate":null,"createdBy":"TAYLORT","dateCreated":"2017-09-14","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"592A743E-A5E2-487D-E053-F662850A9518","beginDate":"2017-09-14","endDate":null,"createdBy":"TAYLORT","dateCreated":"2017-09-14","modifiedBy":"ONEDATA","dateModified":"2017-09-14","deletedIndicator":"No"},{"value":"Score 2","valueDescription":"Mitotic Rate Score 2","ValueMeaning":{"publicId":"5979449","version":"1","preferredName":"Mitotic Rate Score 2","longName":"5979449","preferredDefinition":"A finding of 4-7 mitoses per mm2 (8-14 per 10 hpf).","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Mitotic Rate Score 2","conceptCode":"C138984","definition":"A finding of 4-7 mitoses per mm2 (8-14 per 10 hpf).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"592A743E-A5EE-487D-E053-F662850A9518","latestVersionIndicator":"Yes","beginDate":"2017-09-14","endDate":null,"createdBy":"TAYLORT","dateCreated":"2017-09-14","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"592A743E-A607-487D-E053-F662850A9518","beginDate":"2017-09-14","endDate":null,"createdBy":"TAYLORT","dateCreated":"2017-09-14","modifiedBy":"ONEDATA","dateModified":"2017-09-14","deletedIndicator":"No"},{"value":"Only microinvasion present not graded","valueDescription":"Microinvasive Breast Carcinoma Present Negation Histologic Grade","ValueMeaning":{"publicId":"5979438","version":"1","preferredName":"Microinvasive Breast Carcinoma Present Negation Histologic Grade","longName":"5979438","preferredDefinition":"Ductal carcinoma in situ of the breast with minimal stromal invasion.  Lymph node involvement is uncommon and the prognosis is generally good.: Being or existing in a specified place or at the specified time.: An operation in which a term denies or inverts the meaning of another term or construction.: The degree of abnormality of cancer cells, a measure of differentiation, the extent to which cancer cells are similar in appearance and function to healthy cells of the same tissue type. The degree of differentiation often relates to the clinical behavior of the particular tumor. Based on the microscopic findings, tumor grade is commonly described by one of four degrees of severity. Histopathologic grade of a tumor may be used to plan treatment and estimate the future course, outcome, and overall prognosis of disease. Certain types of cancers, such as soft tissue sarcoma, primary brain tumors, lymphomas, and breast have special grading systems.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Microinvasive Breast Carcinoma","conceptCode":"C40374","definition":"Invasive breast carcinoma measuring 1 mm or less in size.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Present","conceptCode":"C25626","definition":"Being or existing in a specified place or at the specified time.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Negation","conceptCode":"C25594","definition":"An operation in which a term denies or inverts the meaning of another term or construction.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Histologic Grade","conceptCode":"C18000","definition":"The degree of abnormality of cancer cells, a measure of differentiation, the extent to which cancer cells are similar in appearance and function to healthy cells of the same tissue type. The degree of differentiation often relates to the clinical behavior of the particular tumor. Based on the microscopic findings, tumor grade is commonly described by one of four degrees of severity. Histopathologic grade of a tumor may be used to plan treatment and estimate the future course, outcome, and overall prognosis of disease. Certain types of cancers, such as soft tissue sarcoma, primary brain tumors, lymphomas, and breast have special grading systems.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"592848D1-85F5-07D3-E053-F662850A6D47","latestVersionIndicator":"Yes","beginDate":"2017-09-14","endDate":null,"createdBy":"TAYLORT","dateCreated":"2017-09-14","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"592A743E-A640-487D-E053-F662850A9518","beginDate":"2017-09-14","endDate":null,"createdBy":"TAYLORT","dateCreated":"2017-09-14","modifiedBy":"ONEDATA","dateModified":"2017-09-14","deletedIndicator":"No"},{"value":"Score 1","valueDescription":"Mitotic Rate Score 1","ValueMeaning":{"publicId":"5979450","version":"1","preferredName":"Mitotic Rate Score 1","longName":"5979450","preferredDefinition":"A finding of less than or equal to 3 mitoses per mm2 (less than or equal to 7 per 10 hpf).","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Mitotic Rate Score 1","conceptCode":"C138983","definition":"A finding of less than or equal to 3 mitoses per mm2 (less than or equal to 7 per 10 hpf).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"592A743E-A613-487D-E053-F662850A9518","latestVersionIndicator":"Yes","beginDate":"2017-09-14","endDate":null,"createdBy":"TAYLORT","dateCreated":"2017-09-14","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"592A743E-A62C-487D-E053-F662850A9518","beginDate":"2017-09-14","endDate":null,"createdBy":"TAYLORT","dateCreated":"2017-09-14","modifiedBy":"ONEDATA","dateModified":"2017-09-14","deletedIndicator":"No"},{"value":"No residual invasive carcinoma","valueDescription":"Negation Residual Invasive Carcinoma","ValueMeaning":{"publicId":"5979437","version":"1","preferredName":"Negation Residual Invasive Carcinoma","longName":"5979437","preferredDefinition":"An operation in which a term denies or inverts the meaning of another term or construction.: Remaining or left behind.: A carcinoma that is not confined to the epithelium, and has spread to the surrounding stroma.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Negation","conceptCode":"C25594","definition":"An operation in which a term denies or inverts the meaning of another term or construction.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Residual","conceptCode":"C37895","definition":"Remaining or left behind.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Invasive Carcinoma","conceptCode":"C9480","definition":"A carcinoma that is not confined to the epithelium, and has spread to the surrounding stroma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"592848D1-85CD-07D3-E053-F662850A6D47","latestVersionIndicator":"Yes","beginDate":"2017-09-14","endDate":null,"createdBy":"TAYLORT","dateCreated":"2017-09-14","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"592A743E-A636-487D-E053-F662850A9518","beginDate":"2017-09-14","endDate":null,"createdBy":"TAYLORT","dateCreated":"2017-09-14","modifiedBy":"ONEDATA","dateModified":"2017-09-14","deletedIndicator":"No"},{"value":"Score cannot be determined","valueDescription":"Score Indeterminate","ValueMeaning":{"publicId":"5979436","version":"1","preferredName":"Score Indeterminate","longName":"5979436","preferredDefinition":"A number or range of numeric values measuring performance, function, quality, or ability.: Cannot distinguish between two or more possible values in the current context.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Score","conceptCode":"C25338","definition":"A number or range of numeric values measuring performance, function, quality, or ability.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Indeterminate","conceptCode":"C48658","definition":"Cannot distinguish between two or more possible values in the current context.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"592848D1-85A6-07D3-E053-F662850A6D47","latestVersionIndicator":"Yes","beginDate":"2017-09-14","endDate":null,"createdBy":"TAYLORT","dateCreated":"2017-09-14","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"592A743E-A64A-487D-E053-F662850A9518","beginDate":"2017-09-14","endDate":null,"createdBy":"TAYLORT","dateCreated":"2017-09-14","modifiedBy":"ONEDATA","dateModified":"2017-09-14","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008557","version":"1","preferredName":"Lab Results","preferredDefinition":"the results of laboratory tests.","longName":"LAB_RESULTS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B2CFBA7D-D009-7227-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-27","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-27","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"5979446","version":"1","preferredName":"Nottingham Score Mitotic Count Outcome","preferredDefinition":"A numeric representation combining three histologic reporting elements, tubule formation, nuclear pleomorphism and mitotic count, to determine the grade of breast cancer.  The Nottingham Score is a factor in determining the Nottingham Prognostic Index.:The number of mitoses identified under the microscope in tumors.  It is one of the parameters that determine the grade of malignant tumors.  The method of counting varies, according to the specific tumor examined.  Usually the mitotic count is determined based on the number of mitoses per high power field (40X) or 10 high power fields.:The result of an action.","longName":"C25595:C47864:C20200","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Nottingham Score","conceptCode":"C25595","definition":"A numeric representation combining three histologic reporting elements, tubule formation, nuclear pleomorphism and mitotic count, to determine the grade of breast cancer. The Nottingham Score is a factor in determining the Nottingham Prognostic Index.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Mitotic Count","conceptCode":"C47864","definition":"The number of mitoses identified under the microscope in tumors.  It is one of the parameters that determine the grade of malignant tumors.  The method of counting varies, according to the specific tumor examined.  Usually the mitotic count is determined based on the number of mitoses per high power field (40X) or 10 high power fields.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Outcome","conceptCode":"C20200","definition":"The result of an action.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"592A743E-A59D-487D-E053-F662850A9518","latestVersionIndicator":"Yes","beginDate":"2017-09-14","endDate":null,"createdBy":"TAYLORT","dateCreated":"2017-09-14","modifiedBy":"ONEDATA","dateModified":"2017-09-14","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NCI CRF Standards","workflowStatus":"RELEASED","registrationStatus":"Standard","id":"592A743E-A5AE-487D-E053-F662850A9518","latestVersionIndicator":"Yes","beginDate":"2017-09-14","endDate":null,"createdBy":"TAYLORT","dateCreated":"2017-09-14","modifiedBy":"TAYLORT","dateModified":"2019-06-13","changeDescription":"9/19/17 tt released.  9/13/17 tt New VD to incorporate 2017 CAP Nottingham Score guidelines, added CSI per Round 5 finalization task; replaces VD 2432057.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"5506112","version":"1","longName":"Breast","context":"MCL","ClassificationSchemeItems":[{"publicId":"6643181","version":"1","longName":"Initial Diagnosis","context":"MCL"}]},{"publicId":"5635300","version":"1","longName":"Case Report Form (CRF) Modules","context":"NCI Standards","ClassificationSchemeItems":[{"publicId":"5915898","version":"1","longName":"Microscopic Pathology","context":"NCI Standards"}]},{"publicId":"7434158","version":"1","longName":"CTEP CDISC Harmonization","context":"CTEP","ClassificationSchemeItems":[{"publicId":"11422194","version":"1","longName":"CTEP CDISC Diagnosis Microscopic Pathology","context":"CTEP"}]}],"AlternateNames":[{"name":"CTEP","type":"USED_BY","context":"CTEP"},{"name":"MI_MIORRES_MITOSCR","type":"CTEP CDISC CDE","context":"CTEP"}],"ReferenceDocuments":[{"name":"Mitotic rate","type":"Preferred Question Text","description":"Mitotic rate","url":null,"context":"NCI Standards"},{"name":"College of American Pathologists Protocol for the Examination of Specimens From Patients With Invasive Carcinoma of the Breast","type":"REFERENCE","description":"Version: Invasive Breast 4.0.0.0; Protocol Posting Date: June 2017","url":"http://www.cap.org/","context":"NCI Standards"},{"name":"CTEP Text 1","type":"Alternate Question Text","description":"What is the Nottingham mitotic activity score?","url":null,"context":"CTEP"},{"name":"CTEP Text 2","type":"Alternate Question Text","description":"Nottingham mitotic activity score","url":null,"context":"CTEP"}],"origin":"NCI CRF Standards","workflowStatus":"RELEASED","registrationStatus":"Standard","id":"592AEA99-1F1F-5079-E053-F662850AAEA7","latestVersionIndicator":"Yes","beginDate":"2017-09-14","endDate":null,"createdBy":"TAYLORT","dateCreated":"2017-09-14","modifiedBy":"CLOHNES","dateModified":"2022-10-13","changeDescription":"9/19/17 tt released. 9/14/17 tt New CDE to incorporate 2017 CAP Nottingham Score guidelines, added CSI per Round 5 finalization task;  replaces CDE 2431555.","administrativeNotes":"10/12/22 added alt name, 2 AQT, classification for CTEP CDISC Harmonization project cjl;","unresolvedIssues":null,"deletedIndicator":"No"}}